HWHG(SH:600079) Xin Lang Ji Jin·2025-09-03 03:11Group 1 - The A-share pharmaceutical sector remains active, with the only ETF tracking the pharmaceutical index (562050) rising by 1.83%, aiming for a four-day winning streak [1] - Over the past five trading days, more than 30 million yuan has been invested in advance [1] - The pharmaceutical ETF covers 50 leading pharmaceutical companies, focusing on innovative drugs while also considering traditional Chinese medicine [1] Group 2 - Leading innovative drug stocks surged, with the 480 billion yuan market cap giant, Heng Rui Medicine, rising over 5%, and Renfu Medicine hitting the daily limit [1] - Heng Rui Medicine announced conditional approval for its innovative drug, Zemeituosita tablets, and received clinical trial approval for two other drugs [1] - Renfu Medicine also announced the approval of two significant new products for the cardiovascular and cerebrovascular system [1] Group 3 - Huabao Fund believes that innovative drugs remain the strongest theme and are expected to continue [3] - Key clinical data for Chinese innovative drugs will be released at major conferences in the second half of the year, potentially leading to a market surge similar to the May U.S. Oncology Conference [3] - The fund recommends focusing on leading pharmaceutical companies and suggests investing in the pharmaceutical ETF (562050) and its linked fund (024986) [3]